2018 2024 Chagas Disease Management Market | Global Industry Report
Added: (Fri Feb 08 2019)
Pressbox (Press Release) -
2018 2024 Chagas Disease Management Market | Global Industry Report
A Recent Market Study On Chagas Disease And Its Current Trends And Future Insights
Chagas disease or American trypanosomiasis is a tropical parasitic disease caused by Trypanosoma cruzi. It is transmitted by kissing bugs or triatomine bugs. It can also be transmitted through blood transfusions, in pregnancy, and organ transplantation. In early stage of the Chagas disease, the symptoms include swollen lymph nodes, fever, headache, and local swelling at the site of the bite. The chronic symptoms will appear after 8-12 weeks that may include expansion of ventricles leading to heart failure, irregular heartbeat, difficulty in swallowing, and abdominal or colon pain.
Request Sample Report: https://precisionbusinessinsights.com/request-sample?product_id=15817
Rise in the prevalence of Chagas disease due to unhygienic conditions are factors leading to the growth of Chagas disease drugs market. In addition, increase in the R & D of new products are one of the main factors for the market growth. However, lack of awareness regarding the Chagas disease treatment, a limited number of approved products in the current market, and supply chain issues with Chagas disease drugs will hamper the Chagas disease drugs market growth.
The global Chagas disease management market is categorized as under-
1. Type of treatment
Anti-parasitic treatment
Symptomatic treatment
2. Drug type
Benznidazole
Nifurtimox
3. End-users
Hospital, Online and retail pharmacies
And lastly, on the basis of geographical regions, the global Chagas disease management market have five major regions- North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Latin America is the major center for Chagas disease and gradually developing in the rest of world owing to the population mobility from Latin America. Less number of products available in the market for treatment, and poor diagnostic methods to detect in the Latin America region are the major challenges for the Chagas disease treatment market in this region. North America and Europe are the key regions for Chagas disease therapeutic vaccine market owing to increase in the prevalence of Chagas disease.
Some of the key players in Chagas disease therapeutic vaccine market are AstraZeneca (U.K), Bayer AG (Germany), Daiichi Sankyo Company Ltd (Japan), Eisai Co Ltd (Japan), GlaxoSmithKline Plc. (U.K), Grupo Praxis Pharmaceutical SA (Spain), Kancera AB (Sweden), Novartis AG (Switzerland), Laboratorio Elea S.A.C.I.F. y A (Argentina), Oblita Therapeutics BVBA (Belgium), and Sanofi Aventis (France) to name a few. In 2017, Daiichi Sankyo Company Limited and Drugs for Neglected Diseases initiative (DNDi) are collaborated to form a joint research with regard to a new research program, the hit-to-lead project to develop the drugs for Chagas disease and Leishmaniasis.
Global Chagas disease management market is still in the budding stage. Currently, very few players are actively involved in the development of new products for the treatment. Several products are in pipeline that may enter the market near future. Increase in R & D for new products, acquisitions & mergers, collaborations and providing funds to various organizations can fuel the market growth for Chagas disease treatment market. For instance, in 2012, Japans Astellas Pharma signed an agreement with the Drugs for Neglected Diseases initiative (DNDi) to collaborate on drug discovery research for three neglected tropical diseases: leishmaniasis, Chagas disease, and sleeping sickness.
For More Information : https://precisionbusinessinsights.com/market-reports/global-chagas-disease-management-market/